GHK-Cu vs KPV

Both are sold as components of the same multi-peptide research blends, which is where this pairing usually comes up: someone reading a blend's label wants to know what each part of it is. They are different classes of molecule, described in separate literatures, and treated differently by regulators.

What this comparison cannot establish

No study on either research index places both compounds in the same model. The two columns are separate literatures set side by side, not a head-to-head trial, and nothing here supports a conclusion that one compound does more than the other.
A property appearing in both columns does not mean it was measured the same way. The two bodies of work differ in size, in study type, and in how much of each is independent of the parties selling the material.
Neither compound is an approved drug in the United States. Rows describing regulatory or pharmacopoeial status record how each is treated administratively. They are not findings about what either does.
GHK-Cu carries a cosmetic ingredient listing, and a cosmetic ingredient listing speaks to appearance only. Nothing in this comparison describes either compound as affecting the structure or function of the body.

Published properties

Only properties both compounds publish are listed. Every value carries the primary source it came from.

Property	GHK-Cu	KPV
Cas number	89030-95-5 source	67727-97-3 source
Unii	6BJQ43T1I9 source	READ THE DISCREPANCY BEFORE USING THIS. FDA's Global Substance Registration System holds an approved record for "L-lysyl-L-prolyl-L-valine" with the UNII 7V6LGD8S5R, CAS 67727-97-3, formula C16H30N4O4 and molecular weight 342.4344, cross-referenced to PubChem CID 125672. Two other FDA surfaces disagree with it. FDA's own 503A evaluation lists the UNII code for both KPV (free base) and KPV acetate as "Not available", and the withdrawn nomination answered "Does the substance have a UNII code? NO". FDA's public UNII lookup at precision.fda.gov returns "The UNII (7V6LGD8S5R) does not exist" for that code as of this entry. The registry record is recorded here with that conflict stated rather than resolved. source
Molecular formula	C14H22N6O4.Cu (equivalently C14H22CuN6O4) source	C16H30N4O4 source
Molecular weight	401.91 g/mol source	342.43 g/mol source
Appearance	Crystallised from aqueous copper(II) acetate with ethanol it forms dark purple-blue octahedral crystals; in column purification the complex is collected as the elution peak absorbing at 600 nm. Stated under the cosmetic safety review's Method of Manufacture heading for copper tripeptide-1, so it describes the copper complex rather than the uncomplexed peptide. The underlying source is Pickart and Lovejoy, Methods in Enzymology 1987. source	KPV (free base) is described by FDA as a white to off-white lyophilized powder. FDA describes KPV acetate separately as a white to off-white solid powder. source
Solubility	Highly hydrophilic. Octanol / phosphate-buffered-saline distribution coefficients (log D) measured between -2.38 and -2.49 across the pH range 4.5 to 7.4. source	Different for the two forms, and both figures are supplier-sourced. FDA states that KPV (free base) "is soluble in water up to 0.70 mg/mL" and that KPV acetate "is reported to dissolve in water at 5 mg/mL". PROVENANCE: FDA's footnotes attribute the free-base figure to a supplier certificate of analysis and the acetate figure to a supplier product page, not to a published measurement. FDA treats the free base's low solubility as a characterisation gap, writing that because the nominator gave no formulation detail it "cannot evaluate how the physical and chemical characteristics, especially limited water solubility (0.7 mg/mL) and particle size, impact the performance of final products". source
Storage	This is an accelerated stability finding, not a handling instruction. Under forced-degradation testing the complex remained stable in water and in pH 4.5 to 7.4 buffers held at 60 degrees C for at least two weeks, while basic and oxidative stressors, and to a lesser extent acidic stress, caused hydrolytic cleavage with first-order degradation profiles. A 60 degrees C challenge is a stress condition used to measure degradation kinetics; it is not a holding temperature, and the published literature does not establish one. source	READ THE PROVENANCE BEFORE USING THIS. FDA's evaluation reports that lyophilized KPV (free base) "is stable up to 3 years when stored at -20 degrees C in a tightly closed container, up to 2 years at 4 degrees C, and up to 3 months at 15 degrees C", and that on reconstitution "the aqueous solution is recommended to be stored at -80 degrees C for 6 months, at -2 degrees C for 1 month, and 10 degrees C for 1 week". FDA's footnote attributes every one of those figures to a supplier certificate of analysis, not to a published stability study, and FDA states the conclusion as what "is reported" rather than as an agency determination. For KPV acetate, FDA reports a different condition from the nominator's certificate of analysis: "in a sealed container at 2 degrees C to 8 degrees C". There is no United States, European, Japanese or International pharmacopoeial monograph for either form and no approved product label, so no body with standing to determine handling conditions has done so. FDA separately warns that peptides "can be extremely sensitive to product formulation, process, and environmental conditions (e.g., pH, heat (temperature), concentration, in-process related impurities, excipients etc.), which may lead to the aggregation and degradation of peptides", that this "could result in loss of their biological activity", and that significant amounts of aggregates can form during storage. source

What the research does not show

No large, independent, placebo-controlled trial has measured what GHK-Cu does to the appearance of human facial skin. The human work cited here is small, or applies formulations containing several active ingredients at once.
The human wrinkle trials reported in the cosmetic safety review were conducted on palmitoyl tripeptide-1, a different, fatty-acylated ingredient. They are not measurements of GHK-Cu, and nothing in them transfers to it.
In the one randomised human comparison published on CO2 laser-resurfaced skin, blinded evaluators and computer image analysis found no significant difference between the GHK-Cu regimen and the control regimen for redness, wrinkles, or overall skin quality. Only the patients' own satisfaction ratings differed.
The other published human report on facial appearance is a single-patient case in which copper-GHK was delivered together with four other actives by a resurfacing device, so nothing in it can be attributed to copper-GHK on its own.
The mechanistic literature cited here is cell-culture or rodent work rather than human skin. It describes what the molecule does to cells in a dish or to a rat, not what a cosmetic does on a face.
Review articles summarise and interpret existing work; they do not generate new evidence. Several values on this site are drawn from a cosmetic safety review or a narrative review rather than from the primary study behind them.
The human skin-permeation data cited here come from in vitro diffusion cells using excised skin under infinite-dose conditions. That does not establish how much copper crosses intact living skin from a normal cosmetic application.
The purity figure carried in the cosmetic safety review describes tripeptide-1 (GHK), the uncomplexed peptide GHK-Cu is made from, not GHK-Cu itself; that review's Composition/Impurities section carries no entry for copper tripeptide-1 at all. See the starting material purity entry, which sets out the discrepancy in full. The literature reviewed here therefore reports no purity figure for commercial GHK-Cu, and none for any individual supplier or lot, which is what a lot-specific certificate of analysis is for.
The expert-panel safety conclusion for copper tripeptide-1 is stated for the present practices of use and concentration described in that review. It does not extend to concentrations outside the ones surveyed there.
The published research does not establish an optimal topical concentration, vehicle, or frequency for appearance outcomes in people.
Published work does not establish how long any change in the appearance of skin persists once use stops, nor whether outcomes differ by skin type, age, or sex.

What the research does not show about KPV

There is no human data of any kind. Not a weak trial, not an uncontrolled case series, not a pharmacokinetic sample — nothing. FDA searched the published medical literature, ClinicalTrials.gov, its own adverse event system and its foods complaint system, and states that it did not find information on products containing KPV administered to humans by any route. Everything else on this page is chemistry, regulatory record, or animal and cell-culture work.
No clinical trial of KPV has ever been registered. A query of the ClinicalTrials.gov registry on 2026-09-17 returned a total count of 0 for KPV as an intervention and 0 on a free-text search of the whole registry. There is not a completed trial whose results went unpublished, nor a trial under way; there is no trial. source
The evidence base is preclinical and narrow. FDA's reviewers identified pharmacological studies in in vitro and in vivo models and nothing beyond them, and the published work clusters in two areas: rodent gut inflammation (mouse DSS and TNBS colitis, mouse transfer colitis, mouse colitis-associated tumour models) and inflammation in cultured cells. Cell lines and mouse colitis models are not people with a condition, and a result in one is not a prediction about the other. source
A large share of the animal work does not test KPV on its own; it tests a delivery system carrying KPV, and the delivery system is doing much of the work. Laroui 2010 loaded KPV into 400 nm nanoparticles inside an alginate-chitosan hydrogel and reports that "KPV can be delivered at a concentration that is 12,000-fold lower than that of KPV in free solution, but with similar therapeutic efficacy". Xiao 2017 used hyaluronic-acid- functionalised nanoparticles inside a chitosan/alginate hydrogel and reports that the functionalised system performed better than the plain nanoparticle system. Later papers in this line use self-assembled carrier-free nanodrugs, mucoadhesive hydrogels and cross-linked hydrogels. None of that transfers to the raw peptide, and a result obtained with a nanoparticle is a result about the nanoparticle. source
Route of administration in the published work does not match how this compound is supplied or used. The mouse colitis studies delivered KPV in drinking water or by targeted colonic release. The single nomination FDA evaluated proposed a topical cream or gel. FDA's internet survey found the compound promoted instead as "single-API injectable, oral, topical, and nasal spray drug products". No study exists for any of those routes in a person, and the routes studied in rodents are not the routes being sold. source
The one human-tissue permeation experiment found that unaided permeation was undetectable. In dermatomed human cadaver skin, passive diffusion gave KPV permeation below the assay's detection limit; only microneedle abrasion, iontophoresis, or both together produced measurable transport. FDA reads this both ways, noting it "could limit the systemic bioavailability of KPV applied topically" and equally "could also limit the potential usefulness of KPV as a topical therapeutic agent". A topical product that does not cross the stratum corneum is not a mild version of one that does. source
Much of the literature people cite for KPV is not about KPV. FDA records that of the nine references submitted with the nomination, "eight references are studies on various alpha-MSH ... derivatives conducted in animals" and one concerned skin permeation — none was a study of KPV given to humans. FDA separately excluded from its own evaluation the submitted articles describing N-acetylated KPV and the KPV dimer, as "out of the scope of this evaluation". The parent hormone, the acetylated peptide, the dimer and the tripeptide are four different molecules. source
Where a study has compared the parent hormone with the tripeptide directly, they behaved differently. Getting 2003 reports that macrophage activation, measured as release of KC and interleukin-1 beta, "was inhibited by alpha-MSH and MTII but not by KPV", and that KPV "failed to increase cAMP" where the melanocortin agonist did. Anyone extending an alpha-MSH finding to KPV is extending it across a difference that this paper measured. source
Null results exist and are rarely cited. A 2018 study that modified the lysine residue of the tripeptide reports that antimicrobial assays "under a variety of conditions, showed no activity for Ac-KPV-NH2 or the alpha- or epsilon-glycoalkylated analogs". Separately, a published comment on the 2000 antimicrobial paper reports that its authors repeated the growth inhibition assays and could not observe the effect; as abstracted, the experiments they describe used alpha-MSH rather than the tripeptide, so the failed replication bears on the parent hormone directly and on the tripeptide only by association. source
The mechanism is unknown, which makes the animal findings hard to assess. FDA states that "the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown", and that several lines of evidence indicate melanocortin receptors are unlikely to be those targets — KPV did not displace radiolabelled alpha-MSH binding in three preparations, and pharmacological and genetic approaches failed to implicate the MC2, MC3 or MC4 receptors. The proposed alternatives, NF-kappa B inhibition and PepT1-mediated uptake, are proposals in the literature, not established targets. source
There is no toxicology. FDA states that it identified no acute toxicity study, no repeat-dose toxicity study, no genotoxicity study, no developmental or reproductive toxicity study and no carcinogenicity study of either form, and no pharmacokinetic or toxicokinetic study in any species. Unlike BPC-157, where a published preclinical safety package at least exists to argue about, here there is nothing to read. source
The absence of adverse event reports is not a safety finding. FDA retrieved no reports from its adverse event system through December 3, 2025 and no cases from its foods complaint system since 2004 — and states in the same document that reporting is voluntary, that compounders operating under section 503A generally do not report adverse events to FDA, and that it "cannot make definitive conclusions regarding the safety of KPV based on FAERS data alone". An empty database for a substance nobody reports on says nothing. source
FDA considers the substance itself poorly characterised, and the certificates of analysis circulating for it report purity and little else. FDA found no certificate of analysis for the free base in the nomination at all, and states that the ones it found in the literature "only contain purity testing result", with no impurity limits, no aggregate data and no microbiological testing. For the acetate the nominator's certificate gave impurity totals but no identification of any individual impurity. A purity percentage without an impurity profile does not address what FDA names as the concern. source
The naming of this compound does not distinguish the substances being sold. FDA treats KPV (free base) and KPV acetate as different active pharmaceutical ingredients, records that "The CAS number for KPV acetate is the same as that for KPV (free base) in most public references", and lists no UNII code for either. Published work exists on the free acid (H-Lys-Pro-Val-OH), on the amide (H-KPV-NH2) and on the acetylated amide (Ac-KPV-NH2). A figure attached to the name "KPV" in a third-party source cannot be assigned to a specific substance without checking, and the usual identifiers do not settle it. source
The storage and solubility figures published on this site, and on every other site that carries them, trace through FDA's evaluation to supplier product pages and supplier certificates of analysis rather than to a published stability study. They are recorded here because FDA recorded them, with that provenance stated. The one exception is the forced-degradation chemistry, which comes from a peer-reviewed stability-indicating assay and is labelled as such.
Immunogenicity and aggregation have not been assessed for this compound at all. FDA states there is insufficient data to conclude that either form does not present those risks, and notes that peptides as short as two residues have been shown to aggregate. Short does not mean inert.
The anti-doping position is unresolved rather than permissive. No statement from an anti-doping authority naming this compound was retrievable during data entry, and this file does not infer one in either direction from statements about other substances.
The published research does not establish a dose, a route, a schedule, a duration, or a formulation for any use in a person, and it does not establish what happens with long-term use, because no human study of any length has been published.

GHK-Cu monograph · Research index · Reading a certificate of analysis